DARE Dare Bioscience Inc.

0.9
-0.02  -2%
Previous Close 0.91
Open 0.91
Price To Book 3.89
Market Cap 14931653
Shares 16,683,411
Volume 105,636
Short Ratio
Av. Daily Volume 1,518,559

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 4Q 2020.
Sildenafil Cream, 3.6%
Female Sexual Arousal Disorder (FSAD)
Phase 2 top-line data due 2H 2019.
Ovaprene
Contraception
Phase 3 trial to be initiated 2H 2019.
DARE-BV1
Bacterial Vaginosis
Phase 1 trial to be initiated.
DARE-HRT1
Hormone replacement therapy

Latest News

  1. Edited Transcript of DARE earnings conference call or presentation 14-May-19 8:30pm GMT
  2. Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
  3. Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
  4. Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
  5. Edited Transcript of DARE earnings conference call or presentation 4-Apr-19 12:30pm GMT
  6. Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development
  7. DARE: Pipeline Timelines Intact. Several Development-Related Milestones Upcoming
  8. Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
  9. Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
  10. Daré Bioscience Announces Publication of Pharmacokinetics Study of DARE-HRT1, a Potential Hormone Replacement Therapy, in the Journal of Pharmaceutical Sciences
  11. Daré Bioscience, Inc. Regains Listing Compliance on Nasdaq
  12. Daré Bioscience, Inc. to Host Business Update and Full Year 2018 Financial Results Conference Call and Webcast
  13. World-renowned Scientist, Described as the Edison of Medicine by Forbes Magazine, Dr. Robert Langer Joins Daré Bioscience Scientific Advisory Board
  14. Four Healthcare Stocks Heating Up On Monday
  15. Dare Bioscience stock rockets to pace all gainers after positive findings from VVA treatment study
  16. Daré Bioscience, Inc. to Present at the 31st Annual ROTH Conference
  17. Daré Bioscience Announces Publication of Positive Clinical Findings for Vaginal Administration of Tamoxifen for the Treatment of VVA
  18. Daré Bioscience receives notification of second award from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the development of Ovaprene®
  19. Daré Bioscience, Inc. to Present at the Cowen 39th Annual Healthcare Conference
  20. Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference